Has Abdulsalam Al Kassab, MD received payments from drug or device companies?

Yes. Drug and device makers reported $350,709 in general payments to Abdulsalam Al Kassab, MD across 943 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Abdulsalam Al Kassab, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Abdulsalam Al Kassab, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Abdulsalam Al Kassab, MD

Endocrinology, Diabetes & Metabolism · Rochester Hills, MINPI 1477560308

Payments from drug & device makers

$350,709in general payments, 2019–2025

Across 943 payments — averaging $371.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$128K
Abbott$32K
Sanofi-aventis U.S. LLC$29K
Boehringer Ingelheim$29K
Corcept Therapeutics$28K
Merck$25K
plus $80K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	183	$128,190
Abbott	116	$31,884
Sanofi-aventis U.S. LLC	56	$28,950
Boehringer Ingelheim	61	$28,910
Corcept Therapeutics	59	$27,705
Merck	37	$24,672
Lilly USA, LLC	59	$21,444
Bayer	30	$17,807
AstraZeneca(2 entities)	38	$14,360
Ascendis Pharma Endocrinology Inc	11	$6,875
AbbVie	25	$6,146
Recordati_rare_diseases_inc.	5	$3,111
Valeritas, Inc.	6	$2,650
Amgen(2 entities)	35	$2,031
Amryt Pharma Holdings Ltd	5	$996
Zealand Pharma US, Inc.	4	$464
Antares Pharma, Inc.	12	$302
Chiesi USA, Inc.	1	$300
Dexcom, Inc.	14	$286
Radius Health, Inc.	13	$253
Amneal Pharmaceuticals LLC	12	$235
Amarin Pharma, Inc.	14	$230
Xeris Pharmaceuticals, Inc.	12	$225
Medtronic(2 entities)	14	$219
Esperion Therapeutics, Inc.	12	$208
Lifescan, Inc.	8	$162
Senseonics, Incorporated	7	$142
Insulet Corporation	6	$138
Pfizer	7	$122
Halozyme Inc	2	$119
Astellas Pharma US Inc	6	$113
BD	5	$97
Mannkind Corporation	5	$93
Evoke Pharma, Inc.	5	$88
Ipsen Biopharmaceuticals, Inc	4	$88
Amphastar Pharmaceuticals, Inc.	3	$68
Intra-sana Laboratories	1	$67
Verity Pharmaceuticals Inc.	3	$65
Alvogen Inc	3	$64
BETA Bionics, Inc.	3	$63
Johnson & Johnson	3	$58
IBSA Pharma Inc.	3	$51
Ascensia Diabetes Care US Inc.	2	$47
Embecta Corp.	2	$47
Clarus Therapeutics Inc.	2	$46
Currax Pharmaceuticals LLC	3	$44
Kyowa Kirin, Inc.	2	$39
Nevro Corp.	1	$36
Acerus Pharmaceuticals Corporation	2	$35
Acella Pharmaceuticals, LLC	2	$33
Tolmar, Inc.	2	$32
Averitas Pharma Inc.	1	$31
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$30
Companion Medical, Inc.	2	$28
Tandem Diabetes Care, Inc.	1	$23
Madrigal Pharmaceuticals	1	$23
EUSA Pharma (US) LLC	1	$21
Sequel Med Tech, LLC	1	$20
Rhythm Pharmaceuticals, Inc.	1	$20
Neurocrine Biosciences, Inc.	1	$19

How this compares

$350,709 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$298,079

Medicare patients

1,250

Services billed

2,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Rochester Hills

Farah Dawood FarahRochester Hills$14K
Smita BijlaniRochester Hills$9K
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
Lowell SchmeltzFarmington Hills$2.3M
George GrunbergerBloomfield Hills$1.9M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Gary EdelsonFarmington Hills$503K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →